has moved from laboratory promise to approved therapy within a decade.
Treatments for blood disorders now exist and work, at a price that raises its own questions.
The ethical debate is usually framed as therapy against , and the line is less stable than that framing suggests.
Correcting a that causes early death is clearly therapy.
Raising resistance to a common infection sits at the border, and increasing muscle mass or altering height sits beyond it.
Where a society places the line depends on what it currently considers a normal body, which is a historical rather than a biological judgement.
Deaf communities have made this argument for decades about cochlear implants, and the same argument now applies to editing.
A second distinction is technically sharper and matters more.
editing changes the cells of one patient and ends with that patient.
editing changes every subsequent generation and cannot be consented to by the people most affected.
Almost every jurisdiction prohibits the second, and the held even after one researcher breached it publicly.
That episode is instructive because the sanction came from the scientific community before it came from the state.
Access is the question that will arrive sooner than any of this.
A therapy priced at two million dollars per patient is unavailable to the populations in which the relevant disorders are most common.
Health systems respond with , which spreads the cost and transfers the risk of failure to the manufacturer.
That model works where a system can track a patient for fifteen years and not otherwise.
The result is a technology whose distribution will follow administrative capacity rather than medical need.
That is a familiar pattern, and it is the one that ethical debate about tends to obscure.